5 Stocks Ready for Breakouts
at The Street - Fri May 09, 1:41PM CDT
These stocks look ready to break out and trade higher from current levels.
Should You Buy Merrimack Pharmaceuticals (MACK) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:45AM CDT
Merrimack Pharmaceuticals has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Jim Cramer's 'Mad Money' Recap: Bubbles vs. Valuation
at The Street - Thu May 08, 7:22PM CDT
Unlike the dot-com bubble, new companies today can make a profit but choose not to do so, prefering high valuations, Cramer says.
Merrimack Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 3:47PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Ulrik Nielsen, Chief Scientific Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014 at 3:00 p.m. (PT) at the Encore at the Wynn in Las Vegas.
Neuroblastoma Pipeline Review 2014: 32 Companies & 73 Drug profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pzz2k/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - United Therapeutics Corporation - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Celgene Corporation - AEterna Zentaris Inc. - Lixte Biotechnology Holdings, Inc. - Lorus Therapeutics Inc. - Novogen Limited - Threshold Pharmaceuticals, Inc. - Sareum Holdings plc - MabVax Therapeutics, Inc. - Bionucleon Srl - CerRx, Inc. - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - APEIRON Biologics AG - Xcovery, Inc. - Sutro Biopharma, Inc. - Incuron, LLC - Errant Gene Therapeutics, LLC - DEKK-TEC, Inc. - Bexion Pharmaceuticals, LLC. - Cancer Prevention Pharmaceuticals, Inc. - CureFAKtor Pharmaceuticals. LLC For more information visit http://www.researchandmarkets.com/research/9p...roblastoma
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week.
Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials
Marketwire - Wed May 07, 8:04AM CDT
Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA approved pancreatic cancer drug Gemzar(R), then it was NASDAQ's Celgene and its recently FDA approved treatment of Abraxane(R) plus gemcitabine, and now the latest treatment that Nuvilex's Cell-in-a-Box(R) combined with the anticancer drug ifosfamide outperforms is NASDAQ-listed Merrimack Pharmaceuticals and its treatment, the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin.
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma
PR Newswire - Tue May 06, 11:37AM CDT
The U.S. markets on Monday, May 5, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the session 0.19% higher at 1,884.66. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, with the index advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Retrophin Inc. (NASDAQ: RTRX), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Gilead Sciences Inc. (NASDAQ: GILD) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on RTRX, MACK, GILD and RNN can be downloaded upon signing up at:
The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
at The Street - Tue May 06, 9:00AM CDT
The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million.
Upcoming Investor Conferences, Earnings Releases, and Stock Movements - Analyst Notes on Zillow, CME Group, Invesco, Merrimack and Zimmer
PR Newswire - Tue May 06, 7:47AM CDT
Today, Analysts Review released its analysts' notes regarding Zillow, Inc. (NASDAQ: Z), CME Group Inc. (NASDAQ: CME), Invesco Ltd. (NYSE: IVZ), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) and Zimmer Holdings, Inc. (NYSE: ZMH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2076-100free.
Is Merrimack Pharmaceuticals Worth More Than $700 Million?
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 8:30AM CDT
When patients are diagnosed with diseases like pancreatic cancer where survival is measured in months, not years, any advance is an important one. That's why oncologists and patients are watching Merrimack Pharmaceuticals . Merrimack just...
Today's 3 Biotech Blow-Ups
Todd Campbell, The Motley Fool - Motley Fool - Fri May 02, 1:40PM CDT
While the Motley Fool believes investing should be a long term affair, investors should be aware when companies of interest make big moves higher or lower. Such big moves are usually due to important developments that could significantly influence...
Merrimack Pharmaceuticals, Inc. (MACK) Appears Robust as Stock Shoots up 59.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:44AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) was a big mover last session, as the company saw its shares surge a whopping 59.2% on the day
PharmaEngine Announces MM-398 (PEP02) in Combination with 5-FU/LV Met the Primary Endpoint of Overall Survival in Phase 3 Post-Gemcitabine Metastatic Pancreatic Cancer Study
Business Wire - Fri May 02, 3:19AM CDT
PharmaEngine, Inc. (TWO: 4162) announced today in conjunction with Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) that the top line data of the global, open label, three arm randomized phase 3 metastatic pancreatic cancer (NAPOLI-1) study showed that the combination arm of MM-398 (irinotecan liposome injection) with 5-fluorouracil/leucovorin (5-FU/LV) achieved the primary endpoint of overall survival. Median overall survival on the combination arm was 6.1 months as compared to 4.2 months for the control arm of 5-FU/LV. The hazard ratio for overall survival, the trial's primary endpoint, was 0.67, which was statistically significant with a p-value of 0.012. A statistically significant difference in progression-free survival was also observed, and the safety profile of the combination arm was manageable.
Up 50%: Merrimack Pharmaceuticals' Groundbreaking News
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu May 01, 5:30PM CDT
Shares in Merrimack Pharmaceuticals (NASDAQ: MACK) gained over 50% today on great news regarding a phase 3 trial for its MM-398 drug for pancreatic cancer. In combination with 5-flouroacil and leucovorin, MM-398 generated a 1.9 month lift in...
Nasdaq stocks posting largest volume increases
AP - Thu May 01, 5:08PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage increases
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Most active Nasdaq-traded stocks
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Merrimack climbs on pancreatic cancer drug study
AP - Thu May 01, 4:54PM CDT
NEW YORK (AP) — Merrimack Pharmaceuticals said Thursday that patients treated with its experimental pancreatic cancer drug lived longer than patients who received only standard chemotherapy.